A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection

• Status: Not yet recruiting
• Trial end date: 2023-03-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the pharmacokinetic profiles of LP-001, an amoxicillin and clavulanate formulation, for use in pediatric patients with a bacterial infection.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaizen Bioscience Co.
• Treatments: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Clavulanic Acid; Clavulanic Acids

Criteria

Inclusion Criteria:

• Male or female children between 3 months and 24 months of age.

• Written informed consent by the patient's parent or legal guardian and where appropriate.

• Patients recruited from inpatient/urgent care/emergency room with a bacterial infection. Examples of, but not limited to, bacterial infections could include: acute otitis media, community acquired pneumonia, aspiration (pneumonia), urinary tract infections, lymphadenitis, retropharyngeal abscess, peritonsillar abscess, animal or human bite, cellulitis, skin abscess or dental infection.

Exclusion Criteria:

• Definite or suspected personal history or family history of significant hypersensitivity, intolerance, or allergy to penicillin, amoxicillin, amoxicillin clavulanate, or aspartame. History of reaction to multiple allergens (if considered clinically relevant by the principal investigator or designee).

• Children who weigh less than 5 kg or more than 40kg. Patients who are younger than 3 months or older than 24 months (i.e. past their 2nd birthday).

• Patients with a serious underlying disease, including failure to thrive, which could affect the safety, efficacy, or pharmacokinetics of the study medication.

• History or presence of gastrointestinal, hepatic, or renal disease or other conditions known to interfere with the absorption, distribution, metabolism or excretion of study medication.

• History of diarrhea due to Clostridium difficile following treatment with antibiotics.

• Have a serious underlying systemic clinical manifestation that may obscure response to infection (eg, cystic fibrosis, neoplasms, or juvenile diabetes), as determined by the investigator (or designee).

• Have wheezing exacerbation that may require treatment with corticosteroids, as determined by the investigator (or designee).

• Have renal or hepatic dysfunction or insufficiency.

• Have immune dysfunction or are receiving immunosuppressive therapy.

• Have a chronic gastrointestinal condition (eg, malabsorption or inflammatory bowel disease), as determined by the investigator (or designee).

• Have phenylketonuria or history of amoxicillin clavulanate associated cholestatic jaundice.

• Have a systolic blood pressure <60 mmHg or capillary refill >3 seconds.

• Use of any systemic corticosteroids or any amoxicillin product within the previous 96 hours.

• Poor peripheral venous access.

• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days, current enrollment in another clinical study, or previous enrollment in this clinical study.

• Patients who, in the opinion of the investigator (or designee), should not participate in this study.

• Patients related to the sponsor or investigator.